Molecular Cloning and Characterization of p56 Defines a New Family of RasGAP-binding Proteins

Antonio Di Cristofano(Memorial Sloan Kettering Cancer Center), Nick Carpino(State University of New York), Nicolas Dunant(New York Stem Cell Foundation), Gayle Friedland(New York Stem Cell Foundation), Ryûji Kobayashi(Cold Spring Harbor Laboratory), A Strife(Memorial Sloan Kettering Cancer Center), David Wisniewski(Memorial Sloan Kettering Cancer Center), Bayard D. Clarkson(Memorial Sloan Kettering Cancer Center), Pier Paolo Pandolfi, Marilyn D. Resh(New York Stem Cell Foundation)
Journal of Biological Chemistry
February 1, 1998
Cited by 128Open Access
Full Text

Abstract

Chronic myelogenous leukemia (CML) is a disease characterized by the presence of p210(bcr-abl), a chimeric protein with tyrosine kinase activity. Substrates for p210(bcr-abl) are likely to be involved in the pathogenesis of CML. Here we describe the purification, cDNA cloning, and characterization of a 56-kDa tyrosine phosphorylated protein, p56(dok-2) (Dok-2), from p210(bcr-abl) expressing cells. The human dok-2 cDNA encodes a 412-amino acid protein with a predicted N-terminal pleckstrin homology domain as well as several other features of a signaling molecule, including 13 potential tyrosine phosphorylation sites, six PXXP motifs, and the ability to bind to p120(RasGAP). Dok-2 was shown to be 35% identical to p62(dok-1), a recently identified RasGAP binding protein from CML cells, and analysis of the expressed sequence tag data base revealed the presence of at least four additional proteins containing a Dok homology sequence motif. Dok mRNAs were primarily expressed in tissues of hematopoietic origin. These findings strongly suggest that a family of Dok-related proteins exists that bind to RasGAP and may mediate the effects of p210(bcr-abl) in CML.


Related Papers

No related papers found

Powered by citation graph analysis